Allogene Therapeutics, Inc.
ALLO
$2.22
$0.073.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 0.00 | 22.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 0.00 | 22.00K |
| Cost of Revenue | 150.15M | 166.49M | 180.04M | 190.24M | 192.30M |
| Gross Profit | -150.15M | -166.49M | -180.04M | -190.24M | -192.28M |
| SG&A Expenses | 56.78M | 58.53M | 61.12M | 62.93M | 65.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 206.93M | 225.02M | 241.16M | 253.17M | 257.50M |
| Operating Income | -206.93M | -225.02M | -241.16M | -253.17M | -257.48M |
| Income Before Tax | -190.89M | -211.57M | -236.47M | -251.88M | -257.15M |
| Income Tax Expenses | -- | 443.00K | 443.00K | 443.00K | 443.00K |
| Earnings from Continuing Operations | -190.89 | -212.02 | -236.91 | -252.32 | -257.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -190.89M | -212.02M | -236.91M | -252.32M | -257.59M |
| EBIT | -206.93M | -225.02M | -241.16M | -253.17M | -257.48M |
| EBITDA | -194.57M | -212.48M | -228.52M | -239.99M | -243.84M |
| EPS Basic | -0.87 | -0.98 | -1.11 | -1.23 | -1.34 |
| Normalized Basic EPS | -0.54 | -0.60 | -0.65 | -0.71 | -0.78 |
| EPS Diluted | -0.87 | -0.98 | -1.11 | -1.23 | -1.34 |
| Normalized Diluted EPS | -0.54 | -0.60 | -0.65 | -0.71 | -0.78 |
| Average Basic Shares Outstanding | 882.36M | 866.90M | 854.05M | 825.15M | 778.92M |
| Average Diluted Shares Outstanding | 882.36M | 866.90M | 854.05M | 825.15M | 778.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |